Breaking Finance News

Protagonist Therapeutics Inc (NASDAQ:PTGX) has been upgraded to Hold in a report by Zacks Investment Research today.

Yesterday Protagonist Therapeutics Inc (NASDAQ:PTGX) traded -0.16% lower at $24.95. The company’s 50-day moving average is $22.06 and its 200-day moving average is $18.12. The last closing price is up 37.67% from the 200-day moving average, compared to the S&P 500 which has decreased -0.03% over the same time period. 0 shares of the stock traded hands, down from an average trading volume of 97,248

Zacks Investment Research has upgraded Protagonist Therapeutics Inc (NASDAQ:PTGX) to Hold in a report released on 12/1/2016.

See Chart Below

Protagonist Therapeutics Inc (NASDAQ:PTGX)

Protagonist Therapeutics Inc has a 52 week low of $10.02 and a 52 week high of $25.60 The company’s market cap is currently $0.

About Protagonist Therapeutics Inc (NASDAQ:PTGX)

Protagonist Therapeutics, Inc. (Protagonist) is a clinical-stage biopharmaceutical company. The Company has a technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) to address unmet medical needs. Protagonist's primary focus is on developing oral peptide drugs that specifically target biological pathways. Its oral peptides offer targeted delivery to the gastrointestinal (GI) tissue compartment. The Company's initial lead product candidates, PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease (IBD), a GI disease consisting primarily of ulcerative colitis (UC) and Crohn's disease (CD). Protagonist's product candidate beyond IBD is PTG-300, which is an injectable hepcidin mimetic peptide that the Company is developing for the treatment of iron overload disorders, such as transfusion-dependent b-Thalassemia, hereditary hemochromatosis (HH) and sickle cell disease (SCD).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *